Skip to main content
Premium Trial:

Request an Annual Quote

NEOliquid Biopsy Test

NEO New Oncology has launched NEOliquid, a non-invasive cancer diagnostics test that requires a little as 18 milliliters of blood. It identifies clinically relevant, cancer-specific point mutations, insertions, deletions, and gene fusions in circulating cell-free DNA down to an allele frequency of 0.1 percent. NEOliquid comprises 39 genes relevant for the treatment of solid tumors. It enables parallel analysis of both the primary tumor as well as its metastases, capturing the entire heterogeneity of the disease, and can be applied to reveal additional possible therapeutic options for the patient, the company said in a statement. The product is applicable to patients with solid tumors, such as lung, skin, breast, stomach, intestinal or ovarian cancer, or in childhood malignancies such as neuroblastoma.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.